Elucidating the Prevalence, Etiology, and Trajectories of Symptom Clusters in Early Cancer Survivors

阐明早期癌症幸存者症状群的患病率、病因和轨迹

基本信息

  • 批准号:
    10116493
  • 负责人:
  • 金额:
    $ 35.39万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-03-01 至 2023-02-28
  • 项目状态:
    已结题

项目摘要

Basic science discoveries and cancer treatment innovations have led to 15.5 million cancer survivors currently in the United States, and the number of survivors is estimated to reach 20 million by 2026. Cancer and its treatment often cause long-term effects, including both persistent symptoms and functional deficits that negatively impact survivors’ quality of life. Cancer survivors are an ideal population in which to examine multiple co-occurring symptoms, termed “symptom clusters.” A 2017 panel of experts in symptom science convened by the National Institute of Nursing Research (NINR) and the Office of Rare Diseases noted that patients with chronic conditions such as cancer experience an array of symptom clusters that have a negative impact on health-related quality of life (HRQOL). This panel called for advancing symptom science through symptom cluster research to build the evidence base for effective symptom management. Our proposal is in response to an NINR/NCI joint program announcement that emerged from this workshop. Most prior research on symptom clusters in cancer has focused on patients undergoing the acute phase of cancer treatment for specific common cancers often treated in academic referral centers. Our study will address these limitations by focusing on early stage, sociodemographically diverse adult cancer survivors treated in general US oncology practices. We will investigate symptom clusters using data from a previously surveyed cohort of 5,506 adult cancer survivors initially diagnosed between 21-84 years of age with 1 of 7 distinct cancer types who were recruited in partnership with 4 population-based Surveillance, Epidemiology, and Ends Results (SEER) cancer registries in 3 states (CA, NJ, LA). This cohort was first surveyed at a median of 9 months after initial cancer diagnosis with a follow-up survey conducted 6 months later. The SEER registry data include detailed clinical and treatment data, and the survey collected information on 8 domains of symptoms and functional status common and highly impactful in cancer survivors, and numerous other sociodemographic and economic variables. In Aim 1, we will identify the prevalence of symptom clusters and subgroup profiles using innovative psychometric and statistical methods. We will evaluate sociodemographic (e.g., age, sex, race-ethnicity, income, education) and clinical characteristics (e.g., cancer type, stage, treatment, and comorbidity) associated with each symptom cluster and survivor subgroup. In Aim 2 we will investigate the temporal patterns of symptom clusters using state-of-the-art latent transition analysis. In both aims, we will evaluate the role of several mutable factors at the patient and healthcare system levels to inform future interventional research. In Aim 3 we will investigate the association of evidence-based symptom and comorbidity care with the prevalence and trajectory of symptom clusters using linked Medicare claims data for the subgroup of survivors ages 65 and over. Our results will enable a richer understanding of the phenomenon of symptom clusters and will provide a new foundation of knowledge that will help inform future interventions to mitigate the adverse effects of symptom clusters.
基础科学的发现和癌症治疗的创新使1550万癌症幸存者得以幸存

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Arnold L Potosky其他文献

Arnold L Potosky的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Arnold L Potosky', 18)}}的其他基金

Population-based assessment of patient-reported outcomes in adults living with metastatic colorectal cancer
对患有转移性结直肠癌的成人患者报告的结果进行基于人群的评估
  • 批准号:
    10711794
  • 财政年份:
    2023
  • 资助金额:
    $ 35.39万
  • 项目类别:
Elucidating the Prevalence, Etiology, and Trajectories of Symptom Clusters in Early Cancer Survivors
阐明早期癌症幸存者症状群的患病率、病因和轨迹
  • 批准号:
    10355546
  • 财政年份:
    2020
  • 资助金额:
    $ 35.39万
  • 项目类别:
Impact Of Genomic and Personalized Medicine in Women Under 65 With Breast Cancer
基因组和个性化医疗对 65 岁以下乳腺癌女性的影响
  • 批准号:
    8295062
  • 财政年份:
    2012
  • 资助金额:
    $ 35.39万
  • 项目类别:
Impact Of Genomic and Personalized Medicine in Women Under 65 With Breast Cancer
基因组和个性化医疗对 65 岁以下乳腺癌女性的影响
  • 批准号:
    8725081
  • 财政年份:
    2012
  • 资助金额:
    $ 35.39万
  • 项目类别:
Impact of Genomic and Personalized Medicine in Women under 65 with Breast Cancer - Supplement
基因组和个性化医疗对 65 岁以下乳腺癌女性的影响 - 补充材料
  • 批准号:
    9336052
  • 财政年份:
    2012
  • 资助金额:
    $ 35.39万
  • 项目类别:
Impact Of Genomic and Personalized Medicine in Women Under 65 With Breast Cancer
基因组和个性化医疗对 65 岁以下乳腺癌女性的影响
  • 批准号:
    8509628
  • 财政年份:
    2012
  • 资助金额:
    $ 35.39万
  • 项目类别:
Outcomes of Prostate Cancer Androgen Deprivation Therapy
前列腺癌雄激素剥夺疗法的结果
  • 批准号:
    8247007
  • 财政年份:
    2010
  • 资助金额:
    $ 35.39万
  • 项目类别:
Outcomes of Prostate Cancer Androgen Deprivation Therapy
前列腺癌雄激素剥夺疗法的结果
  • 批准号:
    8055410
  • 财政年份:
    2010
  • 资助金额:
    $ 35.39万
  • 项目类别:
Outcomes of Prostate Cancer Androgen Deprivation Therapy
前列腺癌雄激素剥夺疗法的结果
  • 批准号:
    7769070
  • 财政年份:
    2010
  • 资助金额:
    $ 35.39万
  • 项目类别:
Cost-Effectiveness of Hormonal Therapy for Clinically Localized Prostate Cancer
临床局限性前列腺癌激素治疗的成本效益
  • 批准号:
    7821966
  • 财政年份:
    2009
  • 资助金额:
    $ 35.39万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 35.39万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.39万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 35.39万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.39万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 35.39万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 35.39万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.39万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 35.39万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 35.39万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.39万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了